Citryll
Citryll develops therapeutic antibodies that target Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases. Its lead asset, CIT-013, is a monoclonal antibody designed to inhibit ET formation and enhance ET clearance. The company is currently conducting Phase 2a clinical trials focusing on patients with rheumatoid arthritis and hidradenitis suppurativa.
Visit websiteOss, Netherlands
Biotech
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €118.5M
- Funding rounds
- 3
Investors in Citryll
Investors on record for Citryll. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Citryll?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors